细胞色素P450酶1A2基因多态性与度洛西汀抗抑郁临床疗效的关系

被引：9

作者：

刘东波

李淑英

崔鹤

王亚丽

祝宾华

陈放

郭慧荣

机构：

[1] 郑州,郑州大学第一附属医院精神医学科,河南省高等学校临床医学重点学科开放实验室

来源：

中华行为医学与脑科学杂志 | 2014年 / 23卷 / 02期

关键词：

细胞色素P450 1A2; 基因多态性; 度洛西汀; 临床疗效;

D O I：

暂无

中图分类号：

R749.4 [情感性精神病];

学科分类号：

100204 [神经病学];

摘要：

目的研究细胞色素P450酶1A2( CYP1A2)基因C734A及G-2964A位点多态性与度洛西汀临床疗效的关系。方法用度洛西汀对223例抑郁症患者进行为期6周的治疗, 用汉密尔顿抑郁量表( HAMD)评定疗效, 聚合酶链反应扩增及限制性片段长度多态性( PCR-RFLP)检测CYP1A2基因C734A及G-2964A位点单核苷酸多态性, 用单因素方差分析分析两者的关系。结果 (1)223例患者中, C734A突变率为63.64%, G-2964A突变率为26.82%。(2)共计220例患者完成全程治疗。两突变位点联合分析结果表明, 高活性组、中间活性组及低活性组在治疗后的HAMD减分率分别为(56.05±10.13)%、(66.36±8.66)%和(73.82±7.10)%, 3组之间两两比较均差异具有统计学意义(均P<0.01)。结论 CYP1A2基因C734A及G-2964A位点多态性与度洛西汀治疗抑郁症的临床疗效密切相关。

引用

共 15 条

[1]

度洛西汀联合心理干预治疗躯体形式障碍的对照研究 [J].

王俊 ;

徐辉霞 ;

孙守英 .

中华行为医学与脑科学杂志, 2012, 21 (05)

[2]

中国人群中CYP1A2基因G-2964A和C734A多态性分布<英文> [J].

韩兴梅 ;

陈小平 ;

吴启南 ;

蒋长虹 ;

周宏灏 .

Acta Pharmacologica Sinica, 2000, (11)

[3]

Curative Effects of ZHENG-Based Fuzheng-Huayu Tablet on Hepatitis B Caused Cirrhosis Related to CYP1A2 Genetic Polymorphism..[J].Li Qing-Ya;Guo Zhi-Zhong;Deng Xin;Xu Lie-Ming;Gao Yue-Qiu;Zhang Wei;Wang Xiao-Su;Xue Dong-Ying;Lu Yi-Yu;Liu Ping;Su Shi-Bing.Evidence-based complementary and alternative medicine : eCAM.2013,

[4]

CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions [J].

Kuo, Hsiang-Wei ;

Liu, Shu Chih ;

Tsou, Hsiao-Hui ;

Liu, Sheng-Wen ;

Lin, Keh-Ming ;

Lu, Shao-Chun ;

Hsiao, Mei-Chun ;

Hsiao, Chin-Fu ;

Liu, Chia-Yih ;

Chen, Chia-Hui ;

Lu, Mong-Liang ;

Shen, Winston W. ;

Tang, Hwa-Sheng ;

Liu, Shen-Ing ;

Chang, Liang-Huey ;

Wu, Hsiao-Yu ;

Chang, Yao-Sheng ;

Yeh, Teng-Kuang ;

Chen, Andrew C. H. ;

Liu, Yu-Li .

PHARMACOGENOMICS, 2013, 14 (10) :1191-1201

[5]

Duloxetine in the acute and continuation treatment of major depressive disorder [J].

Bochsler, Lanny ;

Olver, James S. ;

Norman, Trevor R. .

EXPERT REVIEW OF NEUROTHERAPEUTICS, 2011, 11 (11) :1525-1539

[6]

CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine [J].

Lin, Keh-Ming ;

Tsou, Hsiao-Hui ;

Tsai, I-Ju ;

Hsiao, Mei-Chun ;

Hsiao, Chin-Fu ;

Liu, Chia-Yih ;

Shen, Winston W. ;

Tang, Hwa-Sheng ;

Fang, Chun-Kai ;

Wu, Chi-Shin ;

Lu, Shao-Chun ;

Kuo, Hsiang-Wei ;

Liu, Shi Chih ;

Chan, Hsiu-Wen ;

Hsu, Ya-Ting ;

Tian, Jia-Ni ;

Liu, Yu-Li .

PHARMACOGENOMICS, 2010, 11 (11) :1535-1543

[7]

In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine [J].

Lobo, Evelyn D. ;

Bergstrom, Richard F. ;

Reddy, Shobha ;

Quinlan, Tonya ;

Chappell, Jill ;

Hong, Quan ;

Ring, Barbara ;

Knadler, Mary Pat .

CLINICAL PHARMACOKINETICS, 2008, 47 (03) :191-202

[8]

The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population [J].

Chen, XP ;

Wang, LQ ;

Zhi, LT ;

Zhou, GQ ;

Wang, HJ ;

Zhang, XM ;

Hao, BT ;

Zhu, YP ;

Cheng, Z ;

He, FC .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (03) :249-259

[9]

Single Nucleotide Polymorphisms and Haplotypes of CYP1A2 in a Japanese Population.[J].Akiko Soyama;Yoshiro Saito;Nobumitsu Hanioka;Keiko Maekawa;Kazuo Komamura;Shiro Kamakura;Masafumi Kitakaze;Hitonobu Tomoike;Kazuyuki Ueno;Yu-ichi Goto;Hideo Kimura;Masaaki Katoh;Kenji Sugai;Osamu Saitoh;Mitsuru Kawai;Teiichi Ohnuma;Taisuke Ohtsuki;Chieko Suzuki;Narihiro Minami;Naoyuki Kamatani;Shogo Ozawa;Jun-ichi Sawada.Drug Metabolism and Pharmacokinetics.2005, 1

[10]

Genetic polymorphism of CYP1A2 in ethiopians affecting induction and expression: Characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1 [J].

Aklillu, E ;

Carrillo, JA ;

Makonnen, E ;

Hellman, K ;

Pitarque, M ;

Bertilsson, L ;

Ingelman-Sundberg, M .

MOLECULAR PHARMACOLOGY, 2003, 64 (03) :659-669

← 1 2 →